Product Description
Carteolol is used alone or together with other medicines to treat increased pressure in the eye that is caused by open-angle glaucoma or a condition called intraocular (in the eye) hypertension. This medicine is a beta-blocker . (Sourced from: https://www.mayoclinic.org/drugs-supplements/carteolol-ophthalmic-route/side-effects/drg-20070992?p=1)
Mechanisms of Action: ADRB1 Antagonist,ADRB2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Belgium | Brazil | Chile | China | Colombia | Czech | Egypt | France | Hong Kong | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Luxembourg | Morocco | Netherlands | Pakistan | Peru | Poland | Portugal | Romania | Saudi Arabia | Slovakia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|